Meeting
2019 Genitourinary Cancers Symposium
The oral α and β tubulin inhibitor, VERU-111, for the treatment of metastatic castration-resistant and androgen blocking agent-resistant prostate cancer in nonclinical toxicity studies.
Authors
Robert H. Getzenberg
Nova Southeastern University Dr. Kiran C Patel College of Allopathic Medicine, Fort Lauderdale, FL
Robert H. Getzenberg , Mario A. Eisenberger , Mark Christopher Markowski , Gary Barnette , Darryl Patrick , Mitchell S. Steiner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 299)
DOI
10.1200/JCO.2019.37.7_suppl.299
Abstract #
299
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven U.K. centers.
First Author: Robert Stevenson
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2020 Genitourinary Cancers Symposium
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.
First Author: Andrew Lachlan Schmidt
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters